Idiopathic pulmonary fibrosis

被引:1392
|
作者
Richeldi, Luca [1 ,2 ,3 ]
Collard, Harold R. [4 ]
Jones, Mark G. [2 ,3 ]
机构
[1] Univ Cattolica Sacro Cuore, Fdn Policlin A Gemelli, Unita Operat Complessa Pneumol, I-00168 Rome, Italy
[2] Univ Southampton, Natl Inst Hlth Res, Southampton Resp Biomed Res Unit, Southampton, Hants, England
[3] Univ Southampton, Clin & Expt Sci, Southampton, Hants, England
[4] Univ Calif San Francisco, Dept Med, San Francisco, CA USA
基金
英国惠康基金;
关键词
MUC5B PROMOTER POLYMORPHISM; INTERSTITIAL LUNG-DISEASE; FORCED VITAL CAPACITY; CONTROLLED-TRIAL; GASTROESOPHAGEAL-REFLUX; ALVEOLAR PROGENITOR; ACUTE EXACERBATION; RANDOMIZED-TRIAL; DOUBLE-BLIND; RISK-FACTOR;
D O I
10.1016/S0140-6736(17)30866-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Idiopathic pulmonary fibrosis is a prototype of chronic, progressive, and fibrotic lung disease. Healthy tissue is replaced by altered extracellular matrix and alveolar architecture is destroyed, which leads to decreased lung compliance, disrupted gas exchange, and ultimately respiratory failure and death. In less than a decade, understanding of the pathogenesis and management of this disease has been transformed, and two disease-modifying therapies have been approved, worldwide. In this Seminar, we summarise the presentation, pathophysiology, diagnosis, and treatment options available for patients with idiopathic pulmonary fibrosis. This disease has improved understanding of the mechanisms of lung fibrosis, and offers hope that similar approaches will transform the management of patients with other progressive fibrotic lung diseases.
引用
收藏
页码:1941 / 1952
页数:12
相关论文
共 50 条
  • [1] Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis
    Strykowski, Rachel
    Adegunsoye, Ayodeji
    IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA, 2023, 43 (02) : 209 - 228
  • [2] Idiopathic pulmonary fibrosis: state of the art for 2023
    Podolanczuk, Anna J.
    Thomson, Carey C.
    Remy-Jardin, Martine
    Richeldi, Luca
    Martinez, Fernando J.
    Kolb, Martin
    Raghu, Ganesh
    EUROPEAN RESPIRATORY JOURNAL, 2023, 61 (04)
  • [3] Comorbidities in idiopathic pulmonary fibrosis: an underestimated issue
    Caminati, Antonella
    Lonati, Chiara
    Cassandro, Roberto
    Elia, Davide
    Pelosi, Giuseppe
    Torre, Olga
    Zompatori, Maurizio
    Uslenghi, Elisabetta
    Harari, Sergio
    EUROPEAN RESPIRATORY REVIEW, 2019, 28 (153)
  • [4] Advances in the management of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis
    Liu, Gabrielle Y.
    Budinger, G. R. Scott
    Dematte, Jane E.
    BMJ-BRITISH MEDICAL JOURNAL, 2022, 377
  • [5] Current and Future Treatment Landscape for Idiopathic Pulmonary Fibrosis
    Bonella, Francesco
    Spagnolo, Paolo
    Ryerson, Chris
    DRUGS, 2023, 83 (17) : 1581 - 1593
  • [6] Idiopathic pulmonary fibrosis: effects and optimal management of comorbidities
    King, Christopher S.
    Nathan, Steven D.
    LANCET RESPIRATORY MEDICINE, 2017, 5 (01) : 72 - 84
  • [7] Evolution and treatment of idiopathic pulmonary fibrosis
    Torrisi, Sebastiano Emanuele
    Kahn, Nicolas
    Vancheri, Carlo
    Kreuter, Michael
    PRESSE MEDICALE, 2020, 49 (02):
  • [8] Idiopathic pulmonary fibrosis: Diagnosis and treatment in 2013
    Israel-Biet, D.
    Juvin, K.
    Tran, K. Dang
    Badia, A.
    Cazes, A.
    Delclaux, C.
    REVUE DE PNEUMOLOGIE CLINIQUE, 2014, 70 (1-2) : 108 - 117
  • [9] The therapy of idiopathic pulmonary fibrosis: what is next?
    Somogyi, Vivien
    Chaudhuri, Nazia
    Torrisi, Sebastiano Emanuele
    Kahn, Nicolas
    Muller, Veronika
    Kreuter, Michael
    EUROPEAN RESPIRATORY REVIEW, 2019, 28 (153)
  • [10] Treatment of Idiopathic Pulmonary Fibrosis
    Abuserewa, Sherif T.
    Duff, Richard
    Becker, Gregory
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (05)